Clinical Trial Update: Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers [Phase 1]

View source ↗

Summary

Phase 1 study exploring whether the NK1 receptor antagonist aprepitant can block opioid reward in non-dependent opiate abusers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heroin Use Disorder
• Opioid Use Disorder
• Substance Use Disorder

Drugs mentioned

• Emend (aprepitant) (aprepitant)

Snippet

Sponsor: Karolinska University Hospital | Conditions: Opioid-Related Disorders, Heroin Dependence | Phase 1 | Status: UNKNOWN